Nitric oxide (NO) is a small free-radical gas synthesised from L-arginine by nitric oxide synthase enzymes and used as a short-lived signalling molecule across the vascular, neural, and immune systems. NO output from eNOS is the terminal step in the canonical BPC-157 angiogenic and cytoprotective cascade.
Definition
Nitric oxide is a small, lipophilic, diffusible free-radical gas. It is enzymatically synthesised from the amino-acid L-arginine in a five-electron oxidation that produces L-citrulline as the co-product, catalysed by one of three nitric oxide synthase isoforms (endothelial NOS, neuronal NOS, inducible NOS). Once produced, NO diffuses freely across cell membranes without needing a transporter, but its biological lifetime is short — on the order of seconds — because it reacts rapidly with oxygen, superoxide, and metalloprotein targets.
The dominant intracellular target in vascular signalling is soluble guanylate cyclase, which NO activates by binding to its heme group. Activated guanylate cyclase produces cyclic GMP, which in turn activates protein kinase G and downstream effectors that produce vasodilation in vascular smooth muscle, inhibit platelet aggregation, suppress leukocyte adhesion to the endothelium, and modulate a wide set of secondary responses across the vasculature and surrounding tissue. NO also signals independently of cyclic GMP through direct S-nitrosylation of cysteine residues on hundreds of target proteins.
How nitric oxide is studied in peptide research
NO output is quantitated by direct measurement (Griess assay for the stable oxidation product nitrite, electrochemical NO microsensor, or fluorescent NO-sensitive probes such as DAF-2 and DAF-FM) on cell-culture supernatant or tissue lysates. Pharmacological NO-synthase inhibition with L-NAME or L-NMMA is the standard approach to confirm that an observed peptide effect is NO-dependent — when the NOS inhibitor reverses the functional outcome, the NO arm of the cascade is implicated as causal.
BPC-157 engagement of the VEGFR2-Akt-eNOS cascade in vascular endothelial cells with NO release as a downstream readout is documented in the Hsieh angiogenesis work (PMID 27847966). The Sikiric group’s nitric-oxide-system synthesis frames NO output as central to the compound’s vascular and cytoprotective findings across the wider BPC-157 literature (PMID 23755725). Extension to ischemic-stress models with collateral-circulation involvement (PMID 35125818) and the 2024 cytoprotection-mechanism review (PMID 38980576) keep NO at the centre of the mechanistic map.
Related terms
- eNOS
- Akt signalling
- VEGFR2
- Angiogenesis
- L-arginine / L-citrulline
- Soluble guanylate cyclase
- Cyclic GMP (cGMP)
Compounds where nitric oxide appears in the mechanism literature
- BPC-157 — NO output downstream of VEGFR2-Akt-eNOS is the terminal step in the canonical mechanistic cascade
- TB-500 — vascular-perfusion and angiogenic findings intersect with NO-system signalling in endothelial-cell models
- GHK-Cu — copper-dependent signalling in endothelial-function research has been examined alongside the NO-system axis
References
- Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl) 2017;95(3):323-333. [PMID 27847966]
- Sikiric P et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des 2014;20(7):1126-1135. [PMID 23755725]
- Sikiric P et al. Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances. World J Gastroenterol 2022;28(1):1-22. [PMID 35125818]
- Sikiric P et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Inflammopharmacology 2024;32(5):3119-3161. [PMID 38980576]
Glossary entries describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.